Latest Options News

A shareholder has lodged an application with the Takeovers Panel challenging FBR Limited’s upcoming extraordinary general meeting resolutions related to significant share placements and funding arrangements with Fidelity International.

Enlitic has signed a binding MoU with GE HealthCare to deliver up to A$50 million in migration services over five years, contingent on a A$10 million equity raise that the company has now initiated.

Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.

Anax Metals has locked in a $3.3 million convertible note investment from Mineral Development Partners, with conditional commitments for up to $100 million to advance the Whim Creek Project and establish a Pilbara base metals hub.

Critica Limited has secured drilling approvals and government funding to explore high-grade heavy rare earth elements at its Aurora and Juno satellite prospects near the flagship Jupiter deposit in Western Australia.

Bio-Gene Technology Limited has raised $2.1 million through a placement and launched a Share Purchase Plan to fund critical safety studies for its flagship insecticide Flavocide®, alongside development of Qcide and strategic initiatives.

MinRex Resources has secured all approvals to commence a fully funded drilling program targeting high-priority copper-gold deposits at the Fraser Range Project in Western Australia, aiming to unlock significant exploration potential.

Enlitic, Inc. has launched a two-tranche institutional placement to raise A$10 million, underpinning its strategic collaboration with GE HealthCare and fueling expansion in AI-enabled medical imaging data migration.

Enlitic has formalised a binding MOU with GE HealthCare to deliver multi-million-dollar migration services, contingent on raising A$10 million through a new capital placement. This partnership and funding round mark a pivotal step in Enlitic’s growth strategy within AI-driven medical imaging.

AdAlta Limited has announced a pro rata renounceable rights offer to raise approximately $1.29 million, aiming to fund its strategic pivot towards licensing CAR-T cell therapies through its subsidiary AdCella. The offer includes new shares and options, underpinned by key insiders and an underwriting agreement.

Neurizon Therapeutics has announced the successful completion of its Open-Label Extension study for NUZ-001 in ALS, revealing significant survival benefits and strong tolerability. The company is on track to release top-line results in Q3 2025 and advance to a pivotal Phase 2/3 trial.

Caspin Resources has raised $2.1 million through a two-tranche equity placement to fund ongoing exploration at its promising Bygoo Tin Project, following encouraging high-grade drill results. The capital raise underscores strong investor confidence as further assay and metallurgical results are anticipated soon.